Mr Piers Gaunt MSc

Cancer Research UK Clinical Trials Unit
Principal Biostatistician

Contact details

Email: p.gaunt@bham.ac.uk

Address: Cancer Research UK Clinical Trials Unit (CRCTU)
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Piers Gaunt is a Principal Biostatistician within the Cancer Research UK Clinical Trials Unit (CRCTU). His research focus is on improving the efficiency of clinical trials.

Qualifications

MSc in Medical Statistics, University of Leicester, 2010
BSc (Hons) Chemistry, University of Nottingham, 2001

Biography

Piers Gaunt worked as a scientist and project manager in the pharmaceutical industry prior to returning to academia in 2009 to undertake a Masters in Medical Statistics. Thereafter he joined the CRCTU within the Biostatistics team working in clinical trials in various cancer types and across all phases. He is responsible for the design, supervision, analysis and reporting of several trials within the CRCTU in both adult and paediatric cancer populations, including soft tissue sarcoma, lung, skin and head and neck.

Piers has a keen interest in improving the efficiency of clinical trials across a broad spectrum of areas. Examples of this are (i) in the implementation of efficient clinical trials methodology such as adaptive trial design, (ii) improving the analysis and reporting of clinical trials by writing software programs and driving improvements to aid report generation to facilitate faster interim analyses, and (iii) driving operational efficiency locally within the CRCTU but also nationally via development of guidelines and supporting the UKCRC Registered Clinical Trials Unit Statistical Operational Group. He also is focussed on several local projects to drive process improvement within the CRCTU.

Piers is fully committed to working to improve patient outcomes with an emphasis on survival and quality of life through efficient clinical trials with appropriate statistical methodology.

Teaching

Piers is a co-module lead for the 20-credit Design and Delivery of Further Clinical Trials module within the MSc in Clinical Trials and provides statistical support for students in their dissertations. This module teaches students a large number of contemporary clinical trial topics including; adaptive trial design, non-inferiority trials, trials in surgery, amongst others.

He also contributes to lectures and assists with small group teaching for the MSc Clinical Trials, MSc in Clinical Oncology, MBChB Medicine and Surgery, BMedSc Medical Science, and provides training for internal staff within the CRCTU.

Other activities

Piers was the vice-chair of the local organising committee for the International Society of Clinical Biostatistics conference that was held in Birmingham in August 2016.

He is also a member of several external Data Monitoring Committees and Trials Steering Committees for clinical trials run by other UK clinical trials units.

Piers is a member of the Independent Scientific Advisory Panel for both the Bone Cancer Research Trust and the Research Advisory Group for Myeloma UK.

Publications

Recent publications

Article

Bernadette, B, Kirton, L, Marec-Bérard, P, Gaspar, N, Laurence, V, Martín-Broto, J, Gelderblom, H, Owens, C, Anderton, J, Strauss, SJ, Wingrove, J, Moroz, V, Whelan, J, Hjalgrim, LL, Wheatley, K & Gaunt, P 2026, 'Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial', British Journal of Cancer. https://doi.org/10.1038/s41416-026-03367-4

Matheson, L, Watson, E, Fulton-Lieuw, T, Mittal, S, Gaunt, P, Sissons, J, Liaskou, E, Gaunt, C, Nankivell, P, Mehanna, H & Brett, J 2026, 'Promoting engagement in patient-initiated follow-up and self-care behaviours: acceptability of the 'ACT now & check-it-out' intervention for head and neck cancer (PETNECK2 study)', BMJ Open, vol. 16, no. 2, e099993. https://doi.org/10.1136/bmjopen-2025-099993

Mehanna, H, Gaunt, P, Kong, A, Hartley, A, Sanghera, P, Forster, M, Sen, M, Paleri, V, Fong, C, Geropantas, D, Srinivasan, D, Garikipati, S, Moleron, R, Casswell, G, Aynsley, E, Ward, A, O'Toole, L, Mirza, A, Firth, C, Humphreys, I, Fulton-Lieuw, T, Roques, T & Nankivell, P 2024, 'CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer', Trials, vol. 25, no. 1, 50. https://doi.org/10.1186/s13063-023-07881-1

Kirton, L, Riley, R, Gaunt, P, Brennan, B & Snell, K 2024, 'Development and internal validation of prognostic models for event-free survival in newly diagnosed Ewing sarcoma patients based on routinely collected clinical characteristics from the European randomised controlled trial, EE2012', BMJ Open, vol. 14, no. 12, e082941. https://doi.org/10.1136/bmjopen-2023-082941

Patel, A, Brock, K, Slade, D, Gaunt, C, Kong, A, Mehanna, H, Billingham, L & Gaunt, P 2024, 'Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial', BMC Medical Research Methodology, vol. 24, no. 1, 11. https://doi.org/10.1186/s12874-024-02142-4

PETNECK2 Research Team, Nankivell, P, Gaunt, P, Gaunt, C, Sissons, J, Liaskou, E, Jefferson, Y, Fulton-Lieuw, T, Mittal, S & Mehanna, H 2024, 'PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial', BMC Cancer, vol. 24, no. 1, 823. https://doi.org/10.1186/s12885-024-12470-9

Simões, R, Gulliford, S, Seddon, B, Dehbi, H-M, Robinson, M, Forsyth, S, Hughes, A, Gaunt, P, Nguyen, T-G, Elston, S, Mohammed, K, Zaidi, S, Miles, E, Hoskin, P, Harrington, K & Miah, A 2024, 'Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose–volume constraints development: a study protocol', BMJ Open, vol. 14, no. 8, e083617. https://doi.org/10.1136/bmjopen-2023-083617

Woll, PJ, Gaunt, P, Gaskell, C, Young, R, Benson, C, Judson, IR, Seddon, BM, Marples, M, Ali, N, Strauss, SJ, Lee, A, Kaur, B, Billingham, L & David, H 2023, 'Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata', British Journal of Cancer, vol. 129, no. 9, pp. 1490-1499. https://doi.org/10.1038/s41416-023-02416-6

Forker, LJ, Bibby, B, Yang, L, Lane, B, Irlam, J, Mistry, H, Khan, M, Valentine, H, Wylie, J, Shenjere, P, Leahy, M, Gaunt, P, Billingham, L, Seddon, BM, Grimer, R, Robinson, M, Choudhury, A & West, C 2023, 'Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma', British Journal of Cancer. https://doi.org/10.1038/s41416-023-02265-3

Homer, V, Yap, C, Bond, S, Holmes, J, Stocken, D, Walker, K, Robinson, EJ, Wheeler, G, Brown, S, Hinsley, S, Schipper, M, Weir, CJ, Rantell, K, Prior, T, Yu, L-M, Kirkpatrick, J, Bedding, A, Gamble, C & Gaunt, P 2022, 'Early phase clinical trials extension to guidelines for the content of statistical analysis plans', BMJ, vol. 376, e068177. https://doi.org/10.1136/bmj-2021-068177

Woll, P, Gaunt, P, Danson, S, Steele, N, Ahmed, S, Mulatero, C, Shah, R, Bhosle, J, Hodgkinson, E, Watkins, B & Billingham, L 2022, 'Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): a randomised, double-blind, placebo-controlled phase II trial', Lung Cancer, vol. 171, pp. 26-33. https://doi.org/10.1016/j.lungcan.2022.07.007

Hasan, Z-U, Ahmed, I, Matin, RN, Homer, V, Lear, JT, Ismail, F, Whitmarsh, T, Green, AC, Thomson, J, Milligan, A, Hogan, S, Van-de-Velde, V, Mitchell-Worsford, L, Kentley, J, Bowden, S, Gaunt, P, Wheatley, K, Proby, CM & Harwood, CA 2022, 'Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)', British Journal of Dermatology, vol. 187, no. 3, pp. 324-337. https://doi.org/10.1111/bjd.20974

Abstract

Mehanna, HM, Gaunt, P, Forster, M, Kong, A, Sen, M, Hartley, A, Geropantas, D, Moleron, R, Ghebretinsea, F, Gaunt, C, Humphreys, I, Nabi, Z, Garikipati, S, MacKenzie, J, Casswell, G, Aynsley, E, Ward, A, Sanghera, P, Paleri, V & Nankivell, P 2025, '1317O Results from CompARE phase III RCT: Neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC)', Annals of Oncology, vol. 36, no. Supplement 2, pp. S768-S768. https://doi.org/10.1016/j.annonc.2025.08.1949

Simoes, R, Seddon, B, Robinson, MH, Shelly, S, Adedoyin, T, Dehbi, H-M, Gaunt, P, Hughes, A, Miles, E, Hoskin, P, Harrington, K, Gulliford, S & Miah, AB 2025, 'PRELIMINARY DOSE-VOLUME CONSTRAINTS PREDICTING SUBCUTANEOUS TISSUE FIBROSIS FOR LIMB SARCOMA USING THE VORTEX AND IMRIS TRIALS', ESMO Rare Cancers, vol. 4, no. C, 100103, pp. 26-26. https://doi.org/10.1016/j.esmorc.2025.100103

Comment/debate

PETNECK2 Research Team, Nankivell, P, Gaunt, P, Gaunt, C, Sissons, J, Liaskou, E, Jefferson, Y, Fulton-Lieuw, T, Mittal, S & Mehanna, H 2024, 'Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial', BMC Cancer, vol. 24, no. 1, 861. https://doi.org/10.1186/s12885-024-12639-2

View all publications in research portal